Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | HNF4A | P41235 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30395776 | 0.91 | ALDH1A1 (0.46) | ALDH1A1HSD17B10HPGDBCL2L1HNF4A | |
| SCHEMBL2373718 | 0.91 | ALDH1A1 (0.46) | ALDH1A1HSD17B10HPGDBCL2L1HNF4A | |
| SCHEMBL2167186 | 0.91 | ALDH1A1 (0.46) | ALDH1A1HSD17B10HPGDBCL2L1HNF4A | |
| Phosphine SCHEMBL27403569 | 0.88 | ALDH1A1 (0.44) | ALDH1A1HSD17B10HPGDBCL2L1HNF4A | |
| Hydrogen Sulfide SCHEMBL27549591 | 0.88 | ALDH1A1 (0.44) | ALDH1A1HSD17B10HPGDBCL2L1HNF4A | |
| SCHEMBL7537444 | 0.86 | ALDH1A1 (0.48) | ALDH1A1HSD17B10HPGDBCL2L1HNF4A | |
| SCHEMBL29108665 | 0.86 | ALDH1A1 (0.45) | ALDH1A1HSD17B10HPGDBCL2L1HNF4A | |
| SCHEMBL11762758 | 0.85 | ALDH1A1 (0.46) | ALDH1A1HSD17B10HPGDBCL2L1HNF4A | |
| SCHEMBL30355086 | 0.85 | ALDH1A1 (0.46) | ALDH1A1HSD17B10HPGDBCL2L1HNF4A | |
| SCHEMBL7922689 | 0.84 | HNF4A (0.45) | ALDH1A1HSD17B10HPGDBCL2L1HNF4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6703507-B2 | NONAQUEOUS LIQUID COMPRISING THE AMMONIUM SALT OF A SULFONATED OR CARBOXYLATED PHOSPHITE LIGAND; USE AS A MEDIA FOR CHEMICAL REACTIONS, INCLUDING THOSE USING TRANSITION METAL CATALYSTS | CELANESE CHEMICALS EUROPE GMBH (DE) | 2004-03-09 | — | — | US | disclosed |
| US-20020161261-A1 | Nonaqueous liquid comprising the ammonium salt of a sulfonated or carboxylated phosphite ligand; use as a media for chemical reactions, including those using transition metal catalysts | CELANESE CHEMICALS EUROPE GMBH (DE) | 2002-10-31 | — | — | US | disclosed |
| US-6472565-B1 | Method for producing aldehydes | CELANESE CHEMICALS EUROPE GMBH (DE) | 2002-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161261-A1 | Nonaqueous liquid comprising the ammonium salt of a sulfonated or carboxylated phosphite ligand; use as a media for chemical reactions, including those using transition metal catalysts | SLC11A2, NSUN2, SSB | ALDH1A1 4700/4885HSD17B10 4264/4885HPGD 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.